Here’s a startling fact: the timing of your kidney transplant after a liver transplant could significantly impact your kidney function down the line. But here’s where it gets controversial—while survival rates for both the patient and the transplanted kidney seem comparable, there’s a notable difference in kidney function that’s raising eyebrows in the medical community. Let’s dive into the details.
A recent study has shed light on the outcomes of kidney transplants performed after liver transplantation (KALT) compared to simultaneous liver-kidney transplants (SLKT) in what’s known as the 'safety net' era. This era began in August 2017 when the Organ Procurement and Transplantation Network (OPTN) introduced specific criteria for SLKT, ensuring patients with chronic renal insufficiency, sustained acute kidney injury, or metabolic diseases linked to renal failure could receive a kidney alongside their liver transplant. However, recognizing that some patients might still need a kidney transplant later, the OPTN established a 'safety net' protocol to allocate kidneys to liver transplant recipients who develop persistent renal dysfunction within a year post-liver transplant.
And this is the part most people miss—while the study found that kidney allograft survival rates were similar between KALT and SLKT, recipients of KALT showed consistently lower estimated glomerular filtration rates (eGFR), a key marker of kidney function. This finding has sparked debates about the long-term implications of delayed kidney transplantation.
The study, led by Dr. Brian Lee, a transplant hepatologist at the Hoag Digestive Health Institute, analyzed data from the OPTN/United Network for Organ Sharing (UNOS) database. It included 2,620 SLKT recipients and 526 KALT recipients who underwent transplantation between January 2018 and December 2021. Interestingly, KALT recipients were more likely to be male and Caucasian compared to SLKT recipients, though age distributions were similar. Additionally, KALT recipients had a higher prevalence of alcohol-related liver disease (43.0% vs. 30.8% in SLKT) and were more likely to have been on dialysis before their transplant (73.2% vs. 53.5%).
At the one-year mark post-kidney transplant, kidney allograft survival rates were nearly identical: 97.7% for KALT and 96.8% for SLKT. However, patient survival rates were slightly higher in the KALT group (96.7% vs. 93.9% in SLKT). The real eye-opener, though, was the eGFR data. KALT recipients consistently showed lower eGFR levels at 6 months, 1 year, and 3 years post-transplant. For instance, at 1 year, the mean eGFR difference was 6.6 mL/min/1.73 m² lower in KALT recipients, even after adjusting for confounding factors.
Here’s where it gets even more intriguing—while initial reports suggested higher rejection rates in KALT recipients, propensity score-matched analyses revealed no significant differences in rejection rates at any time point. This raises questions about the underlying factors contributing to the reduced eGFR in KALT recipients.
So, what does this mean for patients and clinicians? The study underscores the need for longer-term follow-up to determine if the reduced eGFR in KALT recipients translates to poorer kidney health, increased re-transplantation rates, or higher mortality. Additionally, more granular data on immunosuppression protocols, rejection characteristics, and other variables could provide deeper insights.
Now, here’s a thought-provoking question for you: Should the timing of kidney transplantation after liver transplant be reevaluated based on these findings? Or are the current 'safety net' protocols sufficient? Share your thoughts in the comments below—we’d love to hear your perspective!
For clinicians eager to stay updated on the latest in transplant medicine, subscribing to HCPLive could be your next best step. Join thousands of professionals who rely on us for cutting-edge therapies, trial data, and expert insights.
